EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical features of androgen abuse withdrawal in men during the first year of cessation: a community dwelling study

Bonnie Grant iD, Joseph Kean, Nipun Lakshitha de Silva iD, Rodrigo Aguilera, Oliver C B Quinton, Maha Gumssani, Paul Bassett iD, Waljit S Dhillo iD, Anne Lingford-Hughes iD, Kim Wolff iD, Channa N Jayasena iD

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Bonnie Grant und 10 weiteren Autor:innen. Beteiligte Einrichtung: Section of Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London W12 0NN, UK. Hauptthemen laut MEDLINE: Substance Withdrawal Syndrome, Androgens. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MRC, NIHR, NIHR Biomedical Research Centre Funding Scheme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Androgen abuse is an increasing public health concern, particularly among young men seeking muscular or image enhancement. Although most achieve biochemical recovery within 12 months of cessation, mood disturbances, sexual dysfunction, and fatigue are widely reported for years afterward.

Objective

To examine symptom severity the relationship to biochemical recovery during the first year after androgen abuse cessation.

Methods

We conducted a cross-sectional study of community-dwelling men grouped as nonusers, current users, or past users who had ceased within the last 12 months. Participants completed questionnaires on androgen and substance use and 4 validated instruments assessing mood (Beck Depression Inventory-II), anxiety (Generalized Anxiety Disorder-7), sexual function (International Index of Erectile Function-15), and quality-of-life (36-item Short Form). Morning fasted serum hormonal analysis and screening to exclude undisclosed androgen use were performed.

Results

Two hundred forty-seven men were included: 50 nonusers, 125 current users, and 72 past users. Self-reported psychiatric diagnoses were 2.5-fold higher among current and past users than nonusers. Total testosterone (TT) was highest in current users (P < .001) with no difference between past and nonusers. Past users reported significantly worse mood, anxiety, sexual function, and quality of life vs nonusers. Multivariable analyses showed psychiatric comorbidity was independently associated with depression (P = .001), anxiety (P < .001), and poorer quality-of-life (P < .05). Older age and higher luteinizing hormone were associated with reduced sexual function (P < .05), while lower testosterone showed only a modest association with depressive symptoms (P = .03).

Conclusion

Among men in the first year after stopping androgen abuse, psychological symptoms and reduced quality-of-life were most strongly associated with psychiatric comorbidity than biochemical recovery. These findings challenge the assumption that androgen withdrawal symptoms are predominantly driven by hypogonadism and supports developing psychological and behavioral interventions, rather than pharmacological, to support androgen withdrawal in men.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Substance Withdrawal SyndromeAndrogensHumansMaleCross-Sectional StudiesAdultMiddle AgedQuality of LifeDepressionTestosteroneAnxietyAnabolic Androgenic SteroidsSubstance-Related DisordersSurveys and Questionnaires

Stichwörter der Autor:innen

anabolic-androgenic steroidsandrogen abusedepressionerectile dysfunctionhypogonadismtestosteronewithdrawal

Substanzen

AndrogensTestosteroneAnabolic Androgenic Steroids

Autor:innen und Institutionen

  • Section of Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London W12 0NN, UK.
  • BloodWorks Ltd, Bradford BD17 5RT, UK.
  • Department of Clinical Sciences, Faculty of Medicine, General Sir John Kotelawala Defence University, Ratmalana 10370, Sri Lanka.
  • Drug Control Centre, King's Forensics, Faculty of Life Science and Medicine, King's College London, London SE1 9NH, UK.
  • Statsconsultancy Ltd, Bucks HP7 9EN, UK.
  • Division of Psychiatry, Department of Brain Sciences, Imperial College London, London W12 0NN, UK.

ORCID-Profile: Bonnie Grant, Nipun Lakshitha de Silva, Paul Bassett, Waljit S Dhillo, Anne Lingford-Hughes, Kim Wolff, Channa N Jayasena

Förderung

  • MRC
  • NIHR
  • NIHR Biomedical Research Centre Funding Scheme
  • NIHR/Imperial Clinical Research Facility
  • NHS
  • Department of Health
  • NIHR Post-Doctoral Fellowship
  • )

Zitieren

APA

Grant, B., Kean, J., de Silva, N. L., Aguilera, R., Quinton, O. C. B., Gumssani, M., Bassett, P., Dhillo, W. S., Lingford-Hughes, A., Wolff, K., & Jayasena, C. N. (2026). Clinical features of androgen abuse withdrawal in men during the first year of cessation: a community dwelling study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag110

Vancouver

Grant B, Kean J, de Silva NL, Aguilera R, Quinton OCB, Gumssani M, et al. Clinical features of androgen abuse withdrawal in men during the first year of cessation: a community dwelling study. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag110

BibTeX
@article{Grant2026,
  author = {Grant, Bonnie and Kean, Joseph and de Silva, Nipun Lakshitha and Aguilera, Rodrigo and Quinton, Oliver C B and Gumssani, Maha and Bassett, Paul and Dhillo, Waljit S and Lingford-Hughes, Anne and Wolff, Kim and Jayasena, Channa N},
  title = {Clinical features of androgen abuse withdrawal in men during the first year of cessation: a community dwelling study},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag110}
}
Kostenlos starten →